(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Nautilus Biotechnology's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast NAUT's revenue for 2026 to be $90,367,034, with the lowest NAUT revenue forecast at $62,016,592, and the highest NAUT revenue forecast at $119,603,427. On average, 4 Wall Street analysts forecast NAUT's revenue for 2027 to be $987,582,583, with the lowest NAUT revenue forecast at $595,359,281, and the highest NAUT revenue forecast at $1,395,373,315.
In 2028, NAUT is forecast to generate $3,872,872,874 in revenue, with the lowest revenue forecast at $3,720,995,506 and the highest revenue forecast at $3,986,780,900.